Join us for an evening where Japanese deep tech meets Boston's life sciences community. Seven Japanese biotech companies and university research platforms, spanning antibody discovery, RNA and artificial nucleic acid therapeutics, and AI-powered cancer diagnostics, present live at CIC Cambridge, all pre-screened through Hiroshima University's startup selection process.

Meet the founders and researchers building a miRNA therapeutics platform (PURMX Therapeutics), hard-to-target antibody discovery (iBody Inc.), and a non-coding RNA target discovery platform (Cloverna Inc.), alongside university teams from Hiroshima University (host-free DNA synthesis and vaccine manufacturing), Tohoku University (artificial nucleic acid therapeutics for multiple myeloma), Nagoya University (AI-powered diagnostics for pancreatic cancer), and OIST (peptide therapeutics for Alzheimer's disease).

The evening opens with welcome remarks from the Consulate General of Japan in Boston and a look at NINEJP's Japan Innovation Hub initiative, followed by rapid-fire pitches from all seven teams. Then join us for an hour-long poster session where you can talk one-on-one with founders and researchers, dig into the science, and explore licensing, co-development, or investment opportunities directly.

Whether you're a VC scouting early-to-clinical-stage biotech or a pharma or medtech corporate looking for IP structured for licensing or co-development, this is a rare chance to engage with Japan's next wave of life sciences innovation, all under one roof in Cambridge.